摘要
摘要：目的 观察心脉隆联合比索洛尔对冠心病合并心衰患者血清炎症因子及心功能的影响。方法 选择 2015年 11月至 2017年 2月我院收治的冠心病合并心衰患者 88例，根据就诊顺序分为对照组 44例和试验组 44例。对照组应用比索洛尔口服进行治疗，试验组应用心脉隆 +比索洛尔进行联合治疗。观察两组治疗效果。结果 治疗后，对照组超敏 C反应蛋白（ hypersensitive C-reactive protein， hs-CRP）、 B型利钠肽（ Brain natriuretic peptide， BNP）、左室射血分数（ Left Ventricular Ejection Fractions， LVEF）水平均低于试验组，左心室收缩末期容积（ left ventricular end-systolic volume， LVESV）及左心室舒张末期容积（ left ventricular end-diastolic volume， LVEDV）水平高于试验组，差异有统计学意义（ P<0.05）。结论 在冠心病合并心衰患者中应用心脉隆与比索洛尔联合治疗可有效改善炎症因子水平，增强心功能。
关键词：冠心病合并心衰 ;心脉隆 ;比索洛尔 ;血清炎症因子 ;心功能
Abstract: Objective To observe the effect of Xinmailong combined with bisoprolol on serum inflammatory factors and cardiac function in patients with coronary heart disease and heart failure. Methods 88 patients with coronary heart disease and heart failure admitted to our hospital from November 2015 to February 2017 were divided into control group (44 cases) and experimental group (44 cases). The control group was treated with bisoprolol, and the experimental group was treated with propafenone plus bisoprolol. Observe the therapeutic effect of the two groups. Results after treatment, the levels of hypersensitive C-reactive protein (hs CRP), B-type natriuretic peptide (BNP), left ventricular ejection fraction (LVEF) and left ventricular end systolic volume (LVESV) in the control group were lower than those in the experimental group. The level of left ventricular end diastolic volume (LVEDV) was significantly higher than that of the experimental group (P < 0.05). Conclusion the combination therapy of Xinmailong and bisoprolol can effectively improve the level of inflammatory factors and enhance the cardiac function in patients with coronary heart disease and heart failure.
出版日期
2020年04月28日（中国期刊网平台首次上网日期，不代表论文的发表时间）
